Bcl-B Activators
Bcl-B activators are a class of compounds that interact with a protein known as Bcl-B, which is part of the B-cell lymphoma 2 (Bcl-2) family of proteins. These proteins are integral to the regulation of apoptosis, the process of programmed cell death. The Bcl-2 family consists of both pro-apoptotic and anti-apoptotic members, and they function by either promoting or inhibiting the apoptotic process. Bcl-B specifically is categorized within the anti-apoptotic group, which means that it generally acts to preserve cell survival by inhibiting certain mechanisms that lead to apoptosis. Bcl-B activators, therefore, are chemical agents that can influence the activity of Bcl-B protein, often resulting in the modulation of its function.
The structure and function of Bcl-B, like other members of the Bcl-2 family, are characterized by the presence of Bcl-2 homology (BH) domains. These regions are crucial for the interaction of the protein with other molecules, including its homologs and antagonists. Bcl-B activators are designed to bind to these domains, which can lead to a conformational change in the protein, thereby affecting its anti-apoptotic activity. The exact molecular mechanisms through which these activators exert their influence can vary, but they typically involve interactions that either stabilize the protein in a conformation that enhances its anti-apoptotic function or facilitate its interaction with other cellular components that participate in the regulation of apoptosis. The regulation of Bcl-B and its modulation by activators is an area of interest because of its fundamental role in cell survival and homeostasis, which has implications for the intrinsic pathways of cell death and the maintenance of cellular populations.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ABT 737 | 852808-04-9 | sc-207242 | 2.5 mg | $204.00 | 54 | |
ABT-737 is a BH3 mimetic that binds to Bcl-2 family proteins, antagonizing their anti-apoptotic activity. ABT-737 binding to other Bcl-2 family members can displace Bcl-B from heterodimers, indirectly enhancing Bcl-B's pro-apoptotic activity as it may become more available to interact with pro-apoptotic proteins. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Venetoclax is a selective Bcl-2 inhibitor that, like ABT-737, can disrupt Bcl-2/Bcl-XL heterodimers. This disruption can potentially free Bcl-B to interact with pro-apoptotic members of the Bcl-2 family, indirectly enhancing its pro-apoptotic function. | ||||||
ABT 263 | 923564-51-6 | sc-207241 | 5 mg | $245.00 | 16 | |
Navitoclax, another BH3 mimetic, targets Bcl-XL and Bcl-2, releasing pro-apoptotic proteins like Bcl-B from inhibitory complexes. This action can indirectly increase Bcl-B's functional activity by allowing it to form complexes with pro-apoptotic effectors. | ||||||
S63845 | 1799633-27-4 | sc-507518 | 1 mg | $150.00 | ||
S63845 is a selective inhibitor of Mcl-1, a member of the Bcl-2 family. By inhibiting Mcl-1, S63845 may lead to an increased availability of pro-apoptotic proteins such as Bcl-B to exert their function, as they are less likely to be sequestered by Mcl-1. | ||||||
TW-37 | 877877-35-5 | sc-361387 sc-361387A | 10 mg 50 mg | $200.00 $860.00 | 2 | |
TW-37 is a small molecule inhibitor of Bcl-2, Bcl-XL, and Mcl-1. Its action could lead to the displacement of Bcl-B from complexes with these proteins, enhancing Bcl-B's ability to promote apoptosis indirectly. | ||||||
HA14-1 | 65673-63-4 | sc-205911 sc-205911A | 5 mg 25 mg | $59.00 $209.00 | ||
HA14-1 is a small molecule that binds to the BH3-binding groove of Bcl-2, preventing its anti-apoptotic activity. This binding can indirectly enhance Bcl-B's activity by allowing it to more effectively promote apoptosis. | ||||||
Sabutoclax | 1228108-65-3 | sc-472977 | 1 mg | $330.00 | ||
Sabutoclax is a pan-Bcl-2 inhibitor that targets multiple anti-apoptotic Bcl-2 family proteins. By inhibiting these proteins, Sabutoclax could indirectly enhance the pro-apoptotic function of Bcl-B through its increased availability. | ||||||
Obatoclax | 803712-67-6 | sc-507476 | 10 mg | $348.00 | ||
Obatoclax is a BH3 mimetic that inhibits Bcl-2, Bcl-XL, and Mcl-1. Its action may indirectly enhance Bcl-B's pro-apoptotic activity by preventing these proteins from binding and sequestering Bcl-B. | ||||||
A-1210477 | 1668553-26-1 | sc-507474 | 5 mg | $195.00 | ||
A-1210477 is a selective Mcl-1 inhibitor. By preventing Mcl-1 from sequestering pro-apoptotic proteins, A-1210477 could indirectly enhance Bcl-B's pro-apoptotic activity, as Bcl-B would be less likely to be inhibited by Mcl-1. | ||||||
WEHI-539 | 1431866-33-9 | sc-507317 | 5 mg | $233.00 | ||
WEHI-539 is a selective Bcl-XL inhibitor that, by inhibiting Bcl-XL, could lead to an increase in the availability of Bcl-B to promote apoptosis, thereby indirectly enhancing Bcl-B's activity. | ||||||